ASCO 2023 | Updated overall survival findings from the Phase III INTRIGUE trial

Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, discusses overall survival findings from the Phase III INTRIGUE trial (NCT03673501), which assessed ripretinib in patients with gastrointestinal stromal tumor (GIST). Progression-free survival (PFS), the primary endpoint, was not met, and overall survival (OS) was additionally not met. However, a modest improvement in overall survival was observed in patients who were pretreated with imatinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.